A Phase 3 interventional study of Ketamine and Oculus VR headset in Treatment Resistant Depression, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Sunnybrook Health Sciences Centre · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada — 29 open to participants now, 36 under way, 7 of them phase 3. Depressive Disorder, Treatment-Resistant · Canada.
Among the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, this one is the 45th largest by planned enrollment of the 70 interventional ones that give a count, is one of 10 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 24 of the 35 other live ones, and was the 63rd registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →29 of the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada are open now. Recruiting first, the newest first:
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
Joshua Rosenblat · Sites in Canada
Ages 18–70
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
The Royal Ottawa Mental Health Centre · Sites in Canada
Ages 18–75
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 12 · Phase 4 7
First in 2002; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 31 is below the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 50 across the 70 interventional studies, 63 across the 6 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 76 have an industry lead sponsor. The 10 most frequent:
Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sunnybrook Health Sciences Centre has 8 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
12 of the studies in Depressive Disorder, Treatment-Resistant with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262008Phase 3Women's College HospitalSustained Mood Improvement With Laughing Gas Exposure | 2027-02-01 |
| NCT05570344University of AlbertarTMS With and Without Text4Support for the Treatment of Resistant Depression. | 2026-12-31 |
| NCT06163625Unity Health TorontoThe Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression | 2026-12-31 |
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT07212465Rotman Research Institute at BaycrestAccelerated Neuromodulation of Anterior Cingulate Cortex for Depression | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people. There is therefore a need for new treatments which work quickly and effectively.
One such medication is called ketamine. Studies have shown that ketamine can treat symptoms of depression quickly. This quick action sets ketamine apart from many antidepressants that take weeks to show noticeable effects. One way that it may do this is by creating a transient sense or feeling of being separated from reality, such as seeing or hearing things that are not really there. Another way to create these same feelings is with virtual reality (VR), where a person can feel as though they are entering a 3-dimensional virtual computer-generated world by wearing a special headset or goggles with a computer inside.
In this study, all participants will receive standard ketamine treatments for depression. Half of the participants will also use a VR headset while receiving the ketamine treatments to see if ketamine and VR acting together provide a better treatment for symptoms of depression than ketamine alone.
This is a small pilot trial. The main purpose of this trial is to learn if it is possible to run a larger clinical trial comparing "ketamine and VR" with "ketamine alone", for adults with treatment-resistant depression. The researchers will study this by seeing how many participants take part in the study within 1-2 years, and how many complete the study treatments and tests. The researchers will also compare the two study groups to see if "ketamine and VR" provide a better treatment for symptoms of depression than "ketamine alone".
Depression is the single largest contributor to global disability, and afflicts individuals of all ages, races, genders, and classes. The significant morbidity is associated with depressive disorders relates to myriad direct and indirect financial costs to individuals and society. It also bears significant mortality, as one of the strongest risk factors for suicide.
Depression is also challenging to treat, with standard antidepressant therapy providing remission to only one third of patients, and incompletely improving the condition of another one third. Even when standard therapy is effective, it can take as long as six weeks for improvement of cognitive/emotional symptoms to become apparent. The final one third of patients often undergo a therapeutic odyssey in which various medications are attempted with no measurable benefit. Ultimately these patients receive a diagnosis of treatment-resistant depression (TRD).
Ketamine has emerged as a fast-acting intervention for the treatment of depressive disorders, which can reach maximum efficacy in only 24 hours and persist for 1-2 weeks. Ketamine is safe, well-tolerated, familiar to many providers and has become widely available as a treatment for depression.
Virtual reality (VR), a technology which immerses users in a controlled digital experience, has also recently been recognized for its potential in the treatment of mental health disorders and recent studies have identified similarities in proposed mechanisms for ketamine and VR in the treatment of depression (e.g. the creation of a non-ordinary and non-rigid experiences of consciousness, and the production of evocative or hallucinatory sensory experiences). However, this combination of interventions has not yet been studied.
Here, the investigators propose to study the combined effect of ketamine and VR in the vulnerable adult mental health population undergoing ketamine therapy for treatment-resistant depression (TRD).
In Phase I of the study, participants (N=3-5) will provide feedback to develop the VR software for this study population.
In Phase II, study participants (N=26) will be randomized to control (standard of care ketamine alone, Group I) or intervention (VR + ketamine concurrently (VR-K), Group II) groups to report on protocol feasibility and to inform the development of a definitive trial to assess VR-K treatment efficacy. All participants will receive a typical sub-anesthetic dose of ketamine (0.5mg/kg) infused intravenously (IV) over 45 minutes, and will be monitored by research staff for up to 90 minutes post-procedure. Each participant will receive a total of 4 ketamine treatments, 2 treatments per week for 2 weeks. All patients will continue their baseline antidepressant regimens while engaged in the study, consistent with standard ketamine therapy for TRD. Participants in the intervention group will wear a virtual reality headset at the onset of each standard ketamine therapy session, and will be immersed in a tailor-made virtual environment of positive outdoor scenes to provide relaxation and reprieve from negative thoughts.
Psychometric surveys will be used to assess the effects of both treatment arms on mood and psychiatric outcomes (depression and anxiety symptoms), side effects (sedation, dissociation, vitals), cognitive function, neural activity (EEG), and patient satisfaction with virtual reality.
The criteria were revised on the registry on Oct 23, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a standard course of ketamine treatment. At the onset of each ketamine therapy session, participants will be provided with an Oculus VR headset, and will be immersed in a tailor-made virtual environment of positive outdoor scenes.
Drug: Ketamine · Device: Oculus VR headset
Participants will receive a standard course of ketamine treatment.
Drug: Ketamine
Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
Feasibility - Number of Participants who Complete at least 90% of Study Follow-ups
The number of participants who achieve at least 90% completion of follow-ups in Phase II will be calculated.
Time frame: From enrolment until the end of follow-ups at 3 months
Feasibility - Time Required to Complete Enrolment
The time required to enrolled to recruit 26 participants in Phase II of the pilot trial will be recorded.
Time frame: At the time of enrolment
Mood and Psychiatric Outcomes - Montgomery-Åsberg Depression Rating Scale (MADRS)
The MADRS is a 10-item clinician rated scale for measuring severity in the symptoms of depression. Responses for each item are measured on a scale of 0-6 (from no depressive symptomatology to severe depressive symptoms).
Time frame: Baseline, 60 minutes and 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups
Mood and Psychiatric Outcomes - General Anxiety Disorder-7 (GAD-7)
A self-reported questionnaire measuring severity of symptoms of anxiety. The total score on the GAD-7 ranges from 0 to 21, with 0 indicating no anxiety and 21 indicating severe anxiety.
Time frame: Baseline, 60 minutes and 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups
Mood and Psychiatric Outcomes - Positive and Negative Affect Schedule (PANAS)
Self-reported assessment of positive and negative emotions. For positive emotions, scores can range from 10-50, with higher scores representing higher levels of positive affect. For negative emotions, scores can range from 10-50, with lower scores representing lower levels of negative affect.
Time frame: Baseline, 60 minutes and 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups
Mood and Psychiatric Outcomes - Patient Health Questionnaire (PHQ-9)
A self-reported 9-item questionnaire to assess degree of depression severity. Total scores can range from 0 to 27, with higher scores indicating more severe depression.
Time frame: Baseline, 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups
Mood and Psychiatric Outcomes - Beck Depression Inventory-II (BDI-II)
Self-reported questionnaire about symptoms of depression, such as mood, self-dissatisfaction, guilt and fatigue. Scores range from 0 to 63, with higher scores representing higher depression severity.
Time frame: Baseline, 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups
Anti-depressant use
The antidepressant use by participants will be collected.
Time frame: Baseline, 1 and 3 month follow-ups
Ketamine Side Effects - Heart Rate
Heart rate will be collected before, during, and up to 60 minutes after each treatment.
Time frame: Before, continuously during the 45-minute infusion, and up to 60 minutes after each treatment
Ketamine Side Effects - Mean Arterial Pressure
Mean arterial blood pressure will be collected before, during, and up to 60 minutes after each treatment.
Time frame: Before, continuously during the 45-minute infusion, and up to 60 minutes after each treatment
Ketamine Side Effects - Level of consciousness
Participants' level of consciousness will be assessed using the Observer's Assessment of Alertness/Sedation Scale (OAA/S) to establish whether VR engagement is limited by ketamine's effects. The OAA/S score ranges from 1 to 5, with 1 indicating deep sleep/unconsciousness and 5 indicating alertness.
Time frame: At baseline, once during the 45-minute infusion, and up to 60 minutes after each treatment
Ketamine Side Effects - Dissociative Experiences and Psychotomimetic Side Effects
The Clinician Administered Dissociative Symptoms Scale (CADSS-6) will be used to assess dissociative experiences and psychotomimetic side effects (i.e., hallucinations, mild depersonalization, derealization, altered time, body perception). Total scores range from 0 to 24, with higher scores indicating higher levels of dissociation.
Time frame: At baseline, 5-10 minutes after the start of each infusion and 60 minutes after each treatment
Ketamine Side Effects - Mystical Experiences Questionnaire (MEQ)
A 30-item questionnaire for participants to self-report the degree of dissociative and hallucinogenic experiences during the treatment. Each item is scored 0-5, with 0 indicating "none" and 5 indicating "extreme."
Time frame: 60 minutes after each treatment
Ketamine Side Effects - Simulator Sickness Questionnaire
Tolerability of the VR experience will be assessed using the Simulator Sickness Questionnaire (SSQ). Participants will rate the degree to which they experienced 16 symptoms on a scale of 0 to 3, with 0 indicating "not at all" and 3 indicating "severe."
Time frame: At baseline and 60 minutes after each treatment
Cognitive Function - tele-MoCA
Any effect of ketamine and VR-K on cognitive function will be assessed using the telephone Montreal Cognitive Assessment (tele-MoCA). Scores range from 0 to 22, with higher scores indicating less cognitive impairment.
Time frame: Baseline, 1 and 3 month follow-ups
Change in EEG Metrics
The effect of ketamine and VR-K on neural activity will be assessed using a Muse headband with advanced EEG brain sensors (https://ca.choosemuse.com/products/muse-2). Data will be collected using four EEG channels, two each on the anterior frontal (AF) and temporal-parietal (TP) regions, AF7, AF8, TP9, and TP10. Recordings will include data for five brainwaves: alpha, beta, delta, gamma, and theta. The change in EEG metrics will be assessed throughout each treatment and compared between the two treatment groups. Data will be collected using the Muse Lab software.
Time frame: Before, continuously during the 45-minute infusion, and up to 60 minutes after each treatment
Patient Satisfaction - System Usability Scale
Participants in the VR-K group only will be asked to complete a VR system usability scale (VR-SUS) survey for VR technology to evaluate the ease of use of VR technology in this patient population. Participants will indicate their agreement with 8 statements on system usability on a scale of 1-5, with 1 indicating "strongly agree" and 5 indicating "strongly disagree."
Time frame: 60 minutes after the first and final VR-K treatments
Patient Satisfaction - Satisfaction Questionnaire
A satisfaction questionnaire surveying participants' subjective thoughts on the procedure experience. The questionnaire will ask participants' level of agreement with 12 statements regarding their experience (5-level scale, from "strongly agree" to "strongly disagree"), as well as ask about participants' preferences regarding video themes/features (open-ended questions).
Time frame: 60 minutes after the first and final VR-K treatments
Plan to share: Yes — De-identified participant-level data will be made available upon reasonable request to study PI following publication of full trial results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: This is a pilot trial and full inferential analysis will not be conducted until completion of the full trial. As such, data will be available following publication of the primary results of the subsequent full trial.
Access criteria: Data and supporting information will be made available following reasonable request directly to study PI.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →
Sunnybrook Health Sciences Centre →